Drugnews

Updated

Chronic kidney disease: Asian pipelines and global competitors

As of 2026-11-14, Asian CKD programs include UnicoCell’s ELIXCYTE-CKD cell therapy and the IgA-nephropathy products sibeprenlimab from Otsuka and NEFECON from Everest Medicines. Global comparators include investigational balcinrenone/dapagliflozin and finerenone. IgA nephropathy, diabetic kidney disease and broader CKD are distinct populations; indications and approval status are separated below.

Distinct approaches to kidney protection

Selected kidney-protection and disease-modifying approaches; ACE inhibitors, ARBs, SGLT2 monotherapies and dialysis-complication medicines are not exhaustively covered.

Asian companies

AssetCompanyMechanism / routeStageIndicationDeal / rightsLatest verified recordSources
ELIXCYTE-CKD
UnicoCell (Taiwan)
Allogeneic adipose-derived mesenchymal stromal cells
IV
Phase 1/2 completed; Phase 3 IND submitted
Chronic kidney disease
No verified deal terms identified
The 10-01 release confirms continued CKD development; its cell export license is a separate matter, not CKD marketing approval.
sibeprenlimab / VOYXACT
Otsuka / Visterra
Anti-APRIL antibody
SC
US accelerated approval; confirmatory data reported
Adults with primary IgA nephropathy at risk of progression
No verified deal terms identified
Presented final two-year Phase 3 VISIONARY results at ASN; accelerated approval and final data are separate milestones.
NEFECON / targeted-release budesonide
Everest Medicines; originated by Calliditas
Ileum-targeted release budesonide
Oral
Full approval in China
Primary IgA nephropathy
Regionally licensed product; deal amounts not verified
The product page records full China approval in 2025-04; no later dated milestone for this product is supplied on that page.

Global comparators

AssetCompanyMechanism / routeStageIndicationLatest verified recordSources
balcinrenone / dapagliflozin
AstraZeneca
Non-steroidal MRA / SGLT2 inhibition
Oral
Phase 3
Advanced CKD; separate HF-with-CKD program
The 10-30 pipeline snapshot lists Phase 3; the snapshot is not evidence of trial initiation on that date.
finerenone / KERENDIA
Bayer
Non-steroidal mineralocorticoid receptor antagonist
Oral
Approved in diabetes-associated CKD; non-diabetic CKD sNDA accepted
Diabetic / non-diabetic CKD considered separately
Announced FDA acceptance of the non-diabetic CKD sNDA; acceptance is not approval.

Events in the last 90 days

2026-08-17 – 2026-11-14

Sources and downloads

  1. UnicoCell October update — 2026-10-01
  2. UnicoCell CKD Phase 1/2 publication and IND — 2026-02-06
  3. Otsuka VISIONARY final results — 2026-10-23
  4. Otsuka FDA accelerated approval — 2025-11-26
  5. Everest official product page — Undated
  6. AstraZeneca pipeline snapshot — 2026-10-30
  7. Bayer non-diabetic CKD sNDA acceptance — 2026-10-09

Information cutoff 2026-11-14